Evora Biosciences acquires exclusive worldwide rights for digestive fistula treatment from Erganeo
Erganeo and Evora Biosciences signed a world-exclusive license agreement for a breakthrough treatment of digestive fistula.
Erganeo and Evora Biosciences signed a world-exclusive license agreement for a breakthrough treatment of digestive fistula.